Theralase Technologies Inc (TLTFF)

[123414]

Other measures for the first three.

Other Outcome Measures:
Efficacy: Recurrence is defined as the interval from Day 0 to documented recurrence [ Time Frame: The overall efficacy will be evaluated during the course of the study (at 3 and 6 months) ]
Recurrence is defined as any new tumour growth, i.e. any biopsy-confirmed new or recurrent tumour, or positive saline bladder washing cytology. Recurrence endpoint is either:
Recurrence-free survival rate at 3 and 6 months.
Recurrence rate at 3 and 6 months.

https://clinicaltrials.gov/ct2/show/study/NCT03053635?term=tld-1433&rank=1&show_desc=Y#desc